MLD is a rare neurodegenerative disorder where every day counts. The earliest signs are often overlooked—mistaken as more common developmental or behavioral conditions. Through the Think Rare Program, we equip frontline healthcare professionals with the insights and tools to spot these early indicators, intervene sooner, and ultimately change the course of a child’s life.
Our international faculty comprises leading clinicians and researchers committed to transforming the MLD diagnostic journey.
The THINK RARE program is independently developed and managed by EIP with respect to content, topics, and appointed speakers. Unrestricted grants are sought to support EIP's activities; Orchard Therapeutics has provided an unrestricted grant to partially support EIP's work on the early diagnosis of metabolic disorders.
